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MaOBJECTIVES The aim of this study was to identify variables associated with tissue fragment embolization during
transcatheter aortic valve replacement (TAVR).
BACKGROUND Brain magnetic resonance imaging and transcranial Doppler studies have revealed that cerebrovascular
embolization occurs frequently during TAVR. Embolized material may be r thrombotic, tissue derived, or catheter (foreign
material) fragments.
METHODS A total of 81 patients underwent TAVR with a dual ﬁlter–based embolic protection device (Montage Dual
Filter System, Claret Medical, Inc., Santa Rosa, California) deployed in the brachiocephalic trunk and left common carotid
artery. Both balloon-expandable and self-expanding transcatheter heart valves (THVs) were used. Filters were retrieved
after TAVR and sent for histopathological analysis.
RESULTS Overall, debris was captured in 86% of patients. Captured material varied in size from 0.1 to 9.0 mm.
Thrombotic material was found in 74% of patients and tissue-derived debris in 63%. Tissue fragments were found more
often with balloon-expandable THVs (79% vs. 56%; p ¼ 0.05). The embolized tissue originated from the native aortic
valve leaﬂets, aortic wall, or left ventricular myocardium. On multivariable logistic regression analysis, balloon-
expandable THVs (odds ratio: 7.315; 95% conﬁdence interval: 1.398 to 38.289; p ¼ 0.018) and cover index (odds ratio:
1.141; 95% conﬁdence interval: 1.014 to 1.283; p ¼ 0.028) were independent predictors of tissue embolization.
CONCLUSIONS Debris is captured with ﬁlter-based embolic protection in the vast majority of patients undergoing
TAVR. Tissue-derived material is found in 63% of cases and is more frequent with the use of balloon-expandable systems
and more oversizing. (J Am Coll Cardiol Intv 2015;8:718–24) © 2015 by the American College of Cardiology Foundation.T ranscatheter aortic valve replacement (TAVR)is associated with procedure-related neuro-logical events (1,2). The 30-day incidence of
major or disabling stroke is 3.4% to 8%, and most of
these events occur within the ﬁrst 24 to 48 h after
TAVR (3–6). Diffusion-weighted magnetic resonance
imaging studies have revealed new brain defects
after TAVR in up to 80% of cases irrespective of
the access strategy used (7–9). Transcranial Doppler
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AB BR E V I A T I O N S
AND ACRONYM S
ACT = activated clotting time
BAV = balloon aortic
valvuloplasty
EPD = embolic protection
device
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719subclinical new brain lesions may be correlated with
expedited neurocognitive impairment in the long
term (12,13). Predictors of tissue detachment and
embolization to the brain during TAVR are currently
unknown. This study aimed to analyze the association
of patient and procedural variables with embolization
of tissue to the brain during TAVR.SEE PAGE 725
IQR = interquartile range
SAVR = surgical aortic valve
replacement
TAVR = transcatheter aortic
valve replacement
THV = transcatheter heart
valveMETHODS
All patients who underwent TAVR with cerebral pro-
tection using the Montage Dual Filter embolic pro-
tection device (EPD) (Claret Medical, Inc., Santa Rosa,
California) between December 2011 and December
2013 were included in this study (Figure 1). Baseline
characteristics and procedural and outcome data
were prospectively collected in a dedicated database
in accordance with local institutional review board
guidelines. Patients were considered at high opera-
tive risk by heart team consensus. Pre-procedural
planning included a contrast multislice computed
tomography examination. Aortic root calciﬁcation
was quantiﬁed by the Agatston score and further
graded semiquantitatively as follows: grade 1, no
calciﬁcation; grade 2, mildly calciﬁed (small isolated
spots); grade 3, moderately calciﬁed (multiple larger
spots); and grade 4, heavily calciﬁed (extensive cal-
ciﬁcations of all cusps) (14). Patient eligibility for the
EPD required an appropriately sized left commonFIGURE 1 Claret Embolic Protection Device
(Top) Device extended before introduction. (Bottom left) Bending of th
and 1 ﬁlter for the left common carotid artery. (Bottom right) Drawingcarotid artery ($5 mm) and brachiocephalic
artery (# 9 mm) without signiﬁcant stenosis
($70%). The Claret Montage EPD consists of
2 polyurethane mesh ﬁlters with 140-mm
pores mounted on a nitinol frame. Its concept
has been discussed in detail elsewhere (15).
Brieﬂy, via right radial artery access, 1 ﬁlter is
deployed in the brachiocephalic trunk and
1 ﬁlter in the left common carotid artery. Of
note, the left vertebral artery is not protected.
One trained operator performed all EPD
implantations.
TAVR PROCEDURE AND FILTER HANDLING.
All TAVR procedures were performed with
patients under general anesthesia. Patients were
pre-loaded with dual-antiplatelet therapy (aspirin
and clopidogrel). A standardized anticoagulation
regimen with heparin was initiated, aiming for an
activated clotting time (ACT) between 250 and 300 s.
The Montage Dual Filter EPD was deployed before the
introduction of the large-bore TAVR access sheath in
the groin. The remainder of the TAVR evolved
according to standard practice. Both self-expanding
and balloon-expandable transcatheter heart valves
(THVs) were used in this study. After valve implan-
tation, the Claret Montage EPD ﬁlters were recap-
tured and removed. Filters were visually inspected on
site. Filters were cut, and the debris was stored in a
buffered formalin (4%) solution and sent for analysis
to the Department of Pathology.e distal segment and exposure of 1 ﬁlter for the brachiocephalic trunk
illustrating the 2 deployed ﬁlters.
TABLE 1 Baseline Patient Characteristics Also Stratiﬁed for the Presence of
Tissue-Derived Debris
Entire Cohort
(N ¼ 81)
No Tissue
(n ¼ 30)
Tissue
(n ¼ 51)
p
Value
Age, yrs 79 (73–84) 78 (73–83) 81 (73–85) 0.277
Male 46 (57) 16 (53) 30 (59) 0.63
Body surface area, m2 1.9 (1.7–2.0) 1.9 (1.8–2.0) 1.9 (1.7–2.0) 0.434
New York Heart Association
functional class III or higher
61 (75) 23 (77) 38 (81) 0.659
Previous cerebrovascular event 14 (17) 4 (13) 10 (20) 0.471
Previous myocardial infarction 16 (20) 8 (27) 8 (16) 0.231
Previous coronary artery bypass
graft surgery
15 (19) 7 (23) 8 (16) 0.392
Diabetes mellitus 18 (22) 7 (23) 11 (22) 0.854
Hypertension 57 (70) 16 (53) 41 (80) 0.010
Chronic obstructive pulmonary disease 13 (16) 6 (20) 7 (14) 0.536
Peripheral arterial disease 20 (25) 10 (33) 10 (20) 0.167
Permanent pacemaker 8 (10) 5 (17) 3 (6) 0.139
Atrial ﬁbrillation 21 (26) 7 (23) 14 (28) 0.683
Additional variables identifying
high operative risk
Frailty 27 (33) 12 (40) 15 (29) 0.329
Porcelain aorta 7 (9) 2 (7) 5 (10) 1.00
LIMA attached to sternum 3 (4) 2 (7) 1 (2) 0.552
Technically inoperable 21 (26) 7 (23) 14 (28) 0.683
Pre-dementia 2 (3) 2 (7) 0 (0) 0.134
Liver cirrhosis, Child class B 2 (3) 0 (0) 2 (4) 0.528
Baseline echocardiography
Aortic valve area, cm2 0.7  0.3 0.8  0.4 0.7  0.2 0.069
Peak velocity 4.0  0.8 3.9  0.8 4.0  0.8 0.405
Peak gradient, mm Hg 67  25 64  25 69  24 0.444
Mean gradient 40  15 38  16 42  15 0.389
Aortic regurgitation grade III or higher 16 (20) 6 (21) 10 (20) 0.941
Mitral regurgitation grade III or higher 8 (10) 1 (3) 7 (14) 0.246
Baseline MSCT data
Agatston score/1,000 3.0 (1.8–4.1) 3.2 (2.0–5.0) 3.0 (1.8–4.1) 0.594
Minimal anulus diameter, mm 21 (20–24) 23 (20–24) 21 (20–23) 0.175
Maximal anulus diameter, mm 28  3 28  3 27  3 0.140
Mean anulus diameter, mm 24 (23–27) 25 (23–27) 24 (23–26) 0.125
Values are median (interquartile range), n (%), or mean  SD.
LIMA ¼ left internal mammary artery; MSCT ¼ multislice computed tomography.
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720HISTOPATHOLOGY PROCESSING. Debris was dehy-
drated and embedded in parafﬁn and cut into 3- to
4-mm-thick sections. Staining was done with hema-
toxylin and eosin and Movat pentachrome. Mate-
rial of very small size (<0.25 mm) was processed
following the Cellient procedure and stained with
both Giemsa and hematoxylin and eosin. Additional
staining techniques were performed whenever ap-
plicable to identify speciﬁc tissue origin, as previ-
ously described (11).
STATISTICAL ANALYSIS. Categorical variables are
presented as frequencies and percentages as appro-
priate and compared using the Pearson chi-squaretest or the Fisher exact test. Continuous variables
are presented as mean  SD or median (IQR) in case of
a normal or skewed distribution, respectively, and
compared using analysis of variance. Normality of the
distributions was assessed using the Shapiro-Wilks
test. To study the independent predictors of tissue
embolization, logistic regression was performed. The
following variables were deemed pathophysiolog-
ically relevant and included in the multivariable
logistic regression model: valve type, cover index as a
surrogate for oversizing, valve area, need for post-
dilation, and peripheral arterial disease. A maximum
of 5 variables were allowed to enter the multivariable
analysis given the absolute event rate of 51 (63%)
in keeping with the frequency of the dependent
variable y (n/10).
Statistical analyses were performed using SPSS
software version 21.0 (SPSS Inc., Chicago, Illinois).
Statistical signiﬁcance was deﬁned as p < 0.05.RESULTS
A total of 81 patients underwent TAVR with the
Montage Dual Filter EPD. Tables 1 and 2 summarize
baseline patient and procedural characteristics. The
mean age was 79 years (interquartile range [IQR], 73
to 84), and 57% were male. One-third and 26% of
patients were considered to be, respectively, frail or
technically inoperable. Atrial ﬁbrillation was present
in 26%. There was signiﬁcant aortic root calciﬁcation
with a median Agatston score of 3,000 (IQR: 1,800 to
4,100). The transfemoral route was the predominant
access strategy. The CoreValve (Medtronic, Minne-
apolis, Minnesota) was used in 46 cases (69%), the
SAPIEN XT (Edwards Lifesciences, Irvine, California)
in 24 (30%), and Portico (St. Jude Medical, St. Paul,
Minnesota) in 1 case. The mean ACT 30 min after a
heparin bolus was 230  68 s. Balloon pre-dilation
was routine (90%), and post-dilation was required
in more than one-fourth of cases. One patient ex-
perienced a transient ischemic attack 1 week after
successful CoreValve implantation during an episode
of new-onset atrial ﬁbrillation. Two patients expe-
rienced a disabling stroke, 1 patient immediately
after TAVR with a CoreValve complicated by peri-
cardial effusion and 1 patient after TAVR with a
SAPIEN XT valve complicated by valve embolization
and rescue CoreValve implantation, respectively.
Both patients required prolonged cardiopulmonary
resuscitation. These 2 patients died of multiorgan
failure, respectively, 2 and 6 weeks after the index
TAVR procedure. The overall 30-day mortality rate
was 3% (n ¼ 2).
TABLE 2 Procedural Characteristics
Entire Cohort
(N ¼ 81)
No Tissue
(n ¼ 30)
Tissue
(n ¼ 51) p Value
Prosthesis size
Medtronic CoreValve, 26 mm 15 (19) 7 (23) 8 (16) 0.392
Medtronic CoreValve, 29 mm 27 (33) 11 (37) 16 (31) 0.625
Medtronic CoreValve, 31 mm 14 (17) 7 (23) 7 (14) 0.269
St. Jude Medical Portico, 23 mm 1
Edwards SAPIEN XT, 23 mm 6 (7) 2 (7) 4 (8) 1.00
Edwards SAPIEN XT, 26 mm 14 (17) 2 (7) 12 (24) 0.053
Edwards SAPIEN XT, 29 mm 4 (5) 1 (3) 3 (6) 1.00
Access strategy
Transfemoral 75 (93) 26 (87) 49 (96) 0.187
Transapical 4 (5) 2 (7) 2 (4) 0.624
Transsubclavian 2 (3) 2 (7) 0 (0) 0.134
Transiliac 0 (0) 0 (0) 0 (0)
Pre-implantation balloon dilation 73 (90) 28 (93) 45 (88) 0.703
Post-implantation balloon dilation 23 (28) 7 (23) 16 (31) 0.438
Valve in valve 2 (3) 0 (0) 2 (4) 0.528
ACT 15–30 min after bolus 230  68 214  68 239  68 0.154
Procedural time, min 168 (152–205) 167 (157–207) 168 (148–199) 0.50
Fluoroscopy time, min 20.2 (17.2–27.2) 18.9 (16.8–27.1) 21.5 (18.1–27.3) 0.38
Values are n (%), mean  SD, or median (interquartile range).
ACT ¼ activated clotting time.
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721HISTOPATHOLOGY. The Montage Dual Filter EPD was
successfully deployed and retrieved in all patients.
Figure 2 displays the frequency and distribution of
the captured debris. Debris of any type was identiﬁed
in 86% of patients. The median size of debris was 1 mm
(IQR: 0.6 to 1.5 mm) and varied between 0.1 mm and
9 mm. Fibrin and thrombotic material (size varied
from 0.2 to 6.2 mm) was found in 74% of patients.
Tissue-derived debris was present in 63%. Typical
features of the degenerative aortic valve leaﬂets,
notably amorphous calciﬁed material and collage-
nous and proteoglycan matrix with elastic tissue sur-
rounded by endothelial cells (size, 0.2 to 5.5 mm), was
identiﬁed in 27 patients (33%) (Figure 3). Arterial
vessel wall characteristics are depicted in Figure 4.
Collagenous tissue of undetermined origin (either
vessel wall or aortic valve leaﬂet) (size, 0.2 to 1.5 mm)
was recognized in 14 patients (17%). Endothelium
strands (size, 0.2 to 9 mm) were noted in 39 patients
(48%). In 13 patients (16%), the retrieved specimen
contained cardiomyocytes representing myocardial
tissue (size, 0.1 to 1.7 mm) (Figure 5). Small foreign-
body polymer material was present in 8 patients.
Of note, compared with TAVR with self-expanding
systems, tissue-derived debris was found more
often with the balloon-expandable THVs (79% vs.
56%; p ¼ 0.05). Conversely, there was no difference
in the presence of thrombotic material in both THV
designs.
PREDICTORS OF TISSUE EMBOLIZATION. Balloon-
expandable THVs (odds ratio: 7.315; 95% conﬁdence
interval: 1.398 to 38.289; p ¼ 0.018) and cover indexFIGURE 2 Identiﬁcation and Frequency of Captured Debris
The bars represent the relative frequencies of overall debris, thromboti
tissue-derived debris.(odds ratio: 1.141; 95% conﬁdence interval: 1.014
to 1.283; p ¼ 0.028) were independent predictors of
tissue embolization, and a trend toward more tissue
embolization was seen with balloon post-dilation
(odds ratio: 2.607; 95% conﬁdence interval: 0.675
to 10.073; p ¼ 0.17) (Table 3). Further analysis demon-
strated no difference in debris size between the self-
expanding and balloon-expandable platforms.c and tissue-derived debris, and subclassiﬁcation of
FIGURE 3 Typical Aortic Leaﬂet Features
Degenerated aortic leaﬂet fragment with a central ﬁbrous
collagen-rich layer (pink ¼ lamina ﬁbrosa), surrounded by an
edematous layer of ﬁbroblasts with a more proteoglycan-rich
cytoplasm (light blue-pink with blue nuclei ¼ lamina spongiosa);
at the base of the leaﬂet, amorphous calciﬁed material is seen,
as is usually present in a severely calciﬁed aortic valve.
FIGURE 5 Myocardial Tissue
Captured tissue fragment representing heart muscle consisting
of cardiomyocytes (dark-pink) with central (purple-blue) nuclei
and a small layer of ﬁbrous tissue covered by endothelial cells
(endothelium).
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722DISCUSSION
The main ﬁndings of our study using a ﬁlter-based
EPD device during TAVR are the following: 1) cerebral
embolization is almost ubiquitous; 2) thrombotic ma-
terial and tissue-derived debris en route to the brain
was captured in 74% and 63%, respectively; 3) the
captured tissue fragments predominantly originatedFIGURE 4 Arterial Wall Features
Fragment of the arterial wall containing remnants of intima with
endothelial lining (En ¼ light blue) and collagenous tissue
(Co ¼ pink) with a few endothelial cells. Note the presence of
ﬁbrin (Fi ¼ dark pink) and thrombus with white blood cells
(purple) and red blood cells (red).from large arterial structures and the aortic valve;
and 4) use of balloon-expandable THVs and more
oversizing were independent predictors of tissue
embolization.
The incidence of clinically apparent neurological
events after TAVR varies in the literature. Variability
in clinical endpoint deﬁnitions, reporting bias, and
relative underdiagnosis has hampered relevant data
comparison between various reports. The Valve Aca-
demic Research Consortium endorsed a consensus
document on uniform endpoint deﬁnitions (16,17).
A meta-analysis of 13 studies using these Valve Aca-
demic Research Consortium deﬁnitions reported
30-day neurological event and major stroke rates
of 5.7% and 3.2%, respectively (18). Randomized,
controlled trials comparing TAVR with surgical aortic
valve replacement (SAVR) have shown similar 30-day
major/disabling stroke rates with both treatment
modalities, 3.8% for balloon-expandable TAVR versus
2.1% with SAVR (p ¼ 0.20) and 3.9% for self-
expanding TAVR versus 3.1% with SAVR (p ¼ 0.55)
(1,2). Importantly, neurological events may be subtle
and remain undiagnosed. Indeed, in a recent study in
which trained neurologists evaluated all patients
before and after SAVR, the stroke rate was as high
as 17% (19). The high cerebral embolization rate
as detected by using ﬁlters during TAVR is consis-
tent with brain magnetic resonance imaging and
transcranial Doppler studies (7–11). Although most
of these defects remain at ﬁrst sight clinically unno-
ticed, the long-term impact of transient brain is-
chemia and subclinical infarcts is unclear, although
TABLE 3 Multivariable Analysis: Predictors of Tissue Embolization
OR (95% CI) p Value
Valve type 7.315 (1.398–38.289) 0.018
Cover index 1.141 (1.014–1.283) 0.028
Valve area 0.998 (0.990–1.006) 0.61
Post-dilation 2.607 (0.675–10.073) 0.17
PAD 0.530 (0.166–1.687) 0.28
CI ¼ conﬁdence interval; OR ¼ odds ratio; PAD ¼ peripheral arterial disease;
THV ¼ transcatheter heart valve.
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723studies suggest associations with neurocognitive
decline and premature dementia (12,13,20).
The histopathology results presented here extend
our previously reported data (11). In fact, captured
debris seemed even more frequent in the current
study (86% vs. 75%). The presence of thrombotic
material in 74% of patients can be partly explained
by the suboptimal ACT levels as measured 15 to 30
min after the initial heparin bolus. The mean ACT of
230 s was lower than the targeted ACT level of 250 to
300 s. Optimized heparin protocols and potentially
more reliable alternative anticoagulants may reduce
thrombus formation. We found tissue-derived debris
in 63% of patients. In one-third of the patients, the
tissue fragments were consistent with aortic valve
tissue. In another 17%, the identiﬁed collagenous
tissue stemmed either from the aortic valve or
arterial wall. Endothelium strands were noted in one-
half of the study patients. Transcranial Doppler
studies conﬁrmed high-intensity transient signals as a
surrogate for microembolization when crossing a
degenerated aortic valve and subsequent instrumen-
tation within the aortic root including valve posi-
tioning and placement. It is conceivable that these
essential manipulations are equally responsible for
dislodgment of material from the aortic valve and
aorta. The identiﬁcation of myocardial tissue frag-
ments in 4 patients is a novel ﬁnding and most prob-
ably the result of friction against the myocardium by
the stiff guidewire that typically is introduced into the
left ventricle to serve as a rail to advance the THV
delivery across the aortic valve. Our ﬁndings under-
score that detachment and subsequent embolization
of solid tissue fragments may be inherent in contem-
porary TAVR practice. Accordingly, a report from the
PRAGMATIC Plus Initiative demonstrated signiﬁcant
reductions in vascular and bleeding complications
with growing TAVR experience yet no impact on
stroke rate, suggesting that experience alone may not
affect cerebrovascular embolization during TAVR (21).
The frequency of tissue embolization during TAVR
was higher with balloon-expandable THVs compared
with self-expanding THVs (79% vs. 56%; p ¼ 0.05).Use of a balloon-expandable THV and more over-
sizing were particularly associated with tissue embo-
lization. Valve oversizing and inﬂation of a balloon
larger than the actual annular size may hypothetically
coincide with a more vigilant impact on the aortic
root during the actual valve implantation, which
may predispose to tissue dislodgment. Conversely, a
transcranial Doppler study found no difference in the
overall number of high-intensity transient signals
between the self-expanding and the balloon expand-
able THVs; however, more high-intensity transient
signals occurred during the valve positioning with the
balloon-expandable THV and conversely during the
valve deployment with the self-expanding THV (10).
During TAVR, the THV will push aside the degen-
erated native aortic valve. With the ﬁrst-generation
THV designs, some degree of oversizing is recom-
mended to reduce the incidence of paravalvular
regurgitation. As a consequence, more oversizing and
a higher cover index will impose more displacing
forces on the degenerated aortic leaﬂets, which could
explain tissue detachment and embolization. The
trend of more tissue embolization with balloon post-
dilation is in concordance with the ﬁndings of a
large multicenter study on cerebrovascular events
after TAVR that identiﬁed balloon post-dilation as a
signiﬁcant predictor for acute neurological events
(odds ratio: 2.46; 95% conﬁdence interval: 1.07 to
5.67) (5). Second-generation THV designs require less
oversizing and need for post-dilation. Whether these
devices will generate less tissue detachment and ce-
rebral embolization needs to be determined. Balloon
aortic valvuloplasty (BAV) before THV implantation
was standard practice in this case series. BAV by itself
may dislodge debris. The need for pre-BAV may be
debatable. Whether direct THV implantation without
previous BAV would result in less tissue embolization
requires further research.
As the indications for TAVR are shifting to lower
risk and younger patients with severe aortic stenosis,
efforts to reduce cerebral embolization seem appro-
priate and valuable. Filter-based embolic protection
during TAVR may be an effective barrier to prevent
tissue debris from reaching the brain. Randomized
studies are underway to investigate the impact of
ﬁlter-based EPDs on TAVR-related brain lesions as
assessed by magnetic resonance imaging.
STUDY LIMITATIONS. This was a single-center descrip-
tive study with a relatively small number of patients.
Predictors of tissue embolization by multivariable
analysis in this series should be considered hypoth-
esis generating, and our ﬁndings require conﬁrmation
in larger patient cohorts. However, the high frequency
PERSPECTIVES
WHAT IS KNOWN: Cerebral embolization of
debris is common with transcatheter aortic valve
replacement and correlates with ischemic brain
lesions by brain magnetic resonance imaging
studies.
WHAT IS NEW: This study establishes the common
ﬁnding of cerebral embolization with transcatheter
aortic valve replacement procedures, which seems
more frequent after the use of balloon-expandable
transcatheter heart valves and with more
oversizing.
WHAT IS NEXT: Larger studies are required to
conﬁrm our ﬁndings and determine whether use of
embolic protection devices could reduce cerebral
embolization during transcatheter aortic valve
replacement.
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724of debris embolization to the brain in general and tis-
sue fragment embolization in particular offer inter-
esting perspectives. Our results may underestimate
the true incidence of cerebral embolization because
the ﬁlter-based EPD used in this study leaves the
left vertebral artery unprotected, and sampling error
in the histopathology analysis could occur.
CONCLUSIONS
Debris is captured with ﬁlter-based embolic protec-
tion in the vast majority of patients undergoing
TAVR. Tissue-derived material is found in 63% of
cases and is more frequent with the use of balloon-
expandable systems and more oversizing.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Nicolas M. Van Mieghem, Department of Interven-
tional Cardiology, Thoraxcenter, Erasmus Medical
Center, Room Bd 171, ‘s Gravendijkwal 230, 3015 CE
Rotterdam, the Netherlands. E-mail: n.vanmieghem@
erasmusmc.nl.RE F E RENCE S1. Smith CR, Leon MB, Mack MJ, et al. Trans-
catheter versus surgical aortic-valve replacement
in high-risk patients. N Engl J Med 2011;364:
2187–98.
2. Adams DH, Popma JJ, Reardon MJ, et al., the
U.S. CoreValve Clinical Investigators. Transcatheter
aortic-valve replacement with a self-expanding
prosthesis. N Engl J Med 2014;370:1790–8.
3. Daneault B, Kirtane AJ, Kodali SK, et al. Stroke
associated with surgical and transcatheter treat-
ment of aortic stenosis: a comprehensive review.
J Am Coll Cardiol 2011;58:2143–50.
4. Nuis RJ, Van Mieghem NM, Schultz CJ, et al.
Frequency and causes of stroke during or after
transcatheter aortic valve implantation. Am J
Cardiol 2012;109:1637–43.
5. Nombela-Franco L, Webb JG, de Jaegere PP,
et al. Timing, predictive factors, and prognostic
value of cerebrovascular events in a large cohort
of patients undergoing transcatheter aortic valve
implantation. Circulation 2012;126:3041–53.
6. Athappan G, Gajulapalli RD, Sengodan P, et al.
Inﬂuence of transcatheter aortic valve replace-
ment strategy and valve design on stroke after
transcatheter aortic valve replacement: a meta-
analysis and systematic review of literature. J Am
Coll Cardiol 2014;63:2101–10.
7. Ghanem A, Muller A, Nahle CP, et al. Risk and
fate of cerebral embolism after transfemoral aortic
valve implantation: a prospective pilot study with
diffusion-weighted magnetic resonance imaging.
J Am Coll Cardiol 2010;55:1427–32.
8. Kahlert P, Knipp SC, Schlamann M, et al. Silent
and apparent cerebral ischemia after percutaneoustransfemoral aortic valve implantation: diffusion-
weighted magnetic resonance imaging study.
Circulation 2010;121:870–8.
9. Rodes-Cabau J, Dumont E, Boone RH, et al.
Cerebral embolism following transcatheter aortic
valve implantation: comparison of transfemoral
and transapical approaches. J Am Coll Cardiol
2011;57:18–28.
10. Kahlert P, Al-Rashid F, Dottger P, et al. Cere-
bral embolization during transcatheter aortic valve
implantation: a transcranial Doppler study. Circu-
lation 2012;126:1245–55.
11. Van Mieghem NM, Schipper ME, Ladich E, et al.
Histopathology of embolic debris captured during
transcatheter aortic valve replacement. Circulation
2013;127:2194–201.
12. Gress DR. The problem with asymptomatic
cerebral embolic complications in vascular pro-
cedures: what if they are not asymptomatic? J Am
Coll Cardiol 2012;60:1614–6.
13. Vermeer SE, Prins ND, den Heijer T, Hofman A,
Koudstaal PJ, Breteler MM. Silent brain infarcts
and the risk of dementia and cognitive decline.
N Engl J Med 2003;348:1215–22.
14. Tops LF, Wood DA, Delgado V, et al. Nonin-
vasive evaluation of the aortic root with multislice
computed tomography implications for trans-
catheter aortic valve replacement. J Am Coll
Cardiol Img 2008;1:321–30.
15. Naber CK, Ghanem A, Abizaid AA, et al.
First-in-man use of a novel embolic protection
device for patients undergoing transcatheter
aortic valve implantation. EuroIntervention 2012;
8:43–50.16. Leon MB, Piazza N, Nikolsky E, et al. Standard-
ized endpoint deﬁnitions for transcatheter aortic
valve implantation clinical trials: a consensus report
from the valve academic research consortium. J Am
Coll Cardiol 2011;57:253–69.
17. Kappetein AP, Head SJ, Genereux P, et al.
Updated standardized endpoint deﬁnitions for
transcatheter aortic valve implantation: the Valve
Academic Research Consortium-2 consensus
document. J Am Coll Cardiol 2012;60:1438–54.
18. Genereux P, Head SJ, Van Mieghem NM, et al.
Clinical outcomes after transcatheter aortic valve
replacement using valve academic research con-
sortium deﬁnitions: a weighted meta-analysis of
3,519 patients from 16 studies. J Am Coll Cardiol
2012;59:2317–26.
19. Messe SR, Acker MA, Kasner SE, et al. Deter-
mining neurologic outcomes from valve opera-
tions I. Stroke after aortic valve surgery: results
from a prospective cohort. Circulation 2014;129:
2253–61.
20. Gaita F, Corsinovi L, Anselmino M, et al.
Prevalence of silent cerebral ischemia in parox-
ysmal and persistent atrial ﬁbrillation and corre-
lation with cognitive function. J Am Coll Cardiol
2013;62:1990–7.
21. Van Mieghem NM, Chieffo A, Dumonteil N,
et al. Trends in outcome after transfemoral
transcatheter aortic valve implantation. AmHeart J
2013;165:183–92.KEY WORDS aortic stenosis, embolization,
TAVR
